Stuart Bhatt
MD
Medical Oncologist
👥Biography 个人简介
Stuart Bhatt has contributed to the clinical development and application of HDAC inhibitors in T cell lymphomas. HDAC inhibitors (vorinostat, romidepsin, belinostat, panobinostat) represent an important class of approved epigenetic cancer therapeutics, and clinical research defining optimal patient selection, combination strategies, and mechanisms of resistance in T cell lymphomas has been important for clinical implementation.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Stuart Bhatt 的研究动态
Follow Stuart Bhatt's research updates
留下邮箱，当我们发布与 Stuart Bhatt（City of Hope）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment